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Abstract: In recent years, next generation sequencing (NGS) technology has been widely used for the
discovery of novel human papillomavirus (HPV) genotypes, variant characterization and genotyping.
Here, we compared the analytical performance of NGS with a commercial PCR-based assay (Anyplex
II HPV28) in cervical samples of 744 women. Overall, HPV positivity was 50.2% by the Anyplex and
45.5% by the NGS. With the NGS, we detected 25 genotypes covered by Anyplex and 41 additional
genotypes. Agreement between the two methods for HPV positivity was 80.8% (kappa = 0.616) and
84.8% (kappa = 0.652) for 28 HPV genotypes and 14 high-risk genotypes, respectively. We recovered
and characterized 243 complete HPV genomes from 153 samples spanning 40 different genotypes.
According to phylogenetic analysis and pairwise distance, we identified novel lineages and sublineages
of four high-risk and 16 low-risk genotypes. In total, 17 novel lineages and 14 novel sublineages were
proposed, including novel lineages of HPV45, HPV52, HPV66 and a novel sublineage of HPV59.
Our study provides important genomic insights on HPV types and lineages, where few complete
genomes were publicly available.
Keywords: Anyplex II HPV28; cervical cancer; human papillomavirus; next generation sequencing;
rolling-circle amplification
1. Introduction
Human papillomavirus (HPV) is one of the most common sexually transmitted infections and
the principal cause of cervical cancer [1]. HPVs belong to the Papillomaviridae family and are highly
diverse. According to the International Committee on the Taxonomy of Viruses Study Group HPVs
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are classified in genera, species and types based on the L1 open reading frame (ORF), being the most
conserved region of the HPV genome [2]. Different HPV types share less than 90% of the L1 gene
nucleotide sequence [2]. HPV types with a difference in complete viral nucleotide sequence of 1% to
10% and of 0.5% to 1% have been further classified into lineages and sublineages denoted by letters and
numbers, respectively [2–4]. Additionally, HPVs are classified according to their oncogenic potential
into high-risk (hr) and low-risk (lr) genotypes [5,6].
Recent studies indicate that lineages of HPV16, 31 and 58 genotypes have different carcinogenic
properties [3,7–11]. For example, sublineage D2 of HPV16 and lineages A/B of HPV31 are associated
with an increased risk of cervical precancer compared to lineages A and C, respectively [8,9,12].
While the scientific community is mainly focusing on the characterization of hr-HPV, only a limited
number of lr-HPV have been classified and characterized into lineages [13–15].
Modern technological advances have resulted in the development of more than 250 HPV detection
and genotyping methods [16]. The Anyplex II HPV28 (Seegene, Seoul, Korea) is a widely used
commercial PCR-based assay for the simultaneous detection and genotyping of 14 hr and 14 lr HPV
types. This assay with high analytical performance has been clinically validated for cervical cancer
screening and used in HPV vaccine surveillance studies [17–20].
While PCR-based HPV assays detect by design only a limited number of targeted genotypes,
next generation sequencing (NGS) may be an alternative approach for universal HPV detection
and characterization [16,21–25]. This technology facilitated the detection of novel HPV genotypes
and variants [14,22,26] resulting in the identification of 222 HPV types and more than 100 lineages/
sublineages [27,28]. Rolling-circle amplification (RCA) has been developed for the random amplification
of circular DNA genomes, including viruses from the Papillomaviridae family [29]. It was first used for
HPV amplification and sequencing by Rector et al. before the availability of NGS [30], and since then
few studies have used this approach for investigating HPV [14,31,32]. The RCA technology allows
unbiased random amplification of HPV genome without prior knowledge of the sequence and therefore
has a great potential for improving characterization of both known and novel HPV genotypes [26,32,33].
In this study, we aimed to investigate and characterize HPV diversity circulating in healthy young
women attending vaccine surveillance study in Luxembourg using NGS-RCA technology. In addition,
we compared the analytical performance of the Anyplex II HPV28 assay and NGS using RCA for HPV
detection and genotyping. To the best of our knowledge, this is the first large scale study to present
HPV diversity using RCA-NGS in healthy women and compare the analytical performance of a PCR
based genotyping assay with NGS-RCA.
2. Materials and Methods
A total of 744 cervical samples of women (median age: 22, range 18–43) participating in an HPV
vaccination surveillance project were included in the study. More details on the study population
and recruitment process have been published elsewhere [20]. Briefly, cervical samples were collected
with a cervical broom by gynecologists or other physicians and placed in a vial containing PreservCyt
medium of ThinPrep (Hologic, Inc., Bedford, MA, USA) [20,34].
2.1. DNA Extraction
DNA extraction from ThinPrep samples for sequencing and genotyping by the Anyplex II HPV28
was performed using the QIAamp DNA mini kit according to manufacturer’s instructions (Qiagen,
Hilden, Germany) [35]. Prior to genotyping/sequencing DNA extracts were stored at −20 ◦C.
2.2. Anyplex II HPV28
Initially, HPV detection was performed by the Anyplex II HPV28, targeting the L1 gene.
The Anyplex assay can simultaneously identify and distinguish of 14 carcinogenic or hr-HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), and 14 lr-HPV types (6, 11, 26, 40, 42, 43, 44, 53, 54, 61,
69, 70, 73, 82) in two sets. The viral load is defined as high (+++) if a positive signal occurs before
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31 polymerase chain reaction (PCR) cycles, as medium (++) if a positive signal occurs within 31 to
40 PCR cycles, and low if a positive signal occurs after 41 PCR cycles [36].
Real time PCR was performed in two multiplex reactions on the CFX96 real-time thermocycler
(Bio-Rad, Hercules, CA, USA). The human beta-globin housekeeping gene was amplified along with
L1 viral gene, as an internal positive control while water was used as a negative control. All reactions
were performed according to the manufacturer’s instructions and the Seegene viewer software was
used for data recording and interpretation [19].
2.3. Next Generation Sequencing
2.3.1. Library Preparation
Total DNA extracts were enriched using rolling-circle amplification (RCA) technology with the
TempliPhi 100 kit according to manufacturer’s instructions (GE Healthcare Life Sciences, New Jersey,
NJ, USA) [30]. Libraries were prepared using Nextera XT DNA Library Prep Kits (Illumina Inc.,
San Diego, CA, USA) as recommended by manufacturer’s instructions followed by sequencing on
Illumina MiniSeq Platform (Illumina Inc., San Diego, CA, USA). Up to 96 samples were multiplexed
using standard Nextera DNA CD Illumina indices in one run (2 × 150 bp paired-end).
2.3.2. Bioinformatic Analysis
Full Genome Assembly and Annotation
In order to assemble full HPV genome sequences, we followed two complementary approaches.
For both approaches we performed an initial QC step, including visual inspection of FastQC report
for each sample [37]. The strictness of applied quality criteria depended on the subsequent approach
followed (Supplementary Figure S1A,B).
The first approach was to “blindly” assemble all reads from 744 samples (irrelevant of being
HPV positive or negative) remaining after filtering against human, bacterial, plasmid and fungal
reference sequences. The second approach was based on assemblies done on only dehumanized reads,
which have been pre-mapped to all available HPV reference genome sequences. In both approaches
mapping was performed with Bowtie2 [38] and de novo assembly with SPAdes (v. 3.13.0) [38,39].
Annotation of genomes was completed by means of an adapted version of VAPiD [40]. Detailed
information on methods and annotation is provided in Supplementary Materials.
We obtained 75 identical genomes by both methods, 86 not fully identical, 42 only with blind
assembly and 43 only with bowtie assembly. We selected 75 identical genomes, while not identical
genomes were compared and further processed to allow assembly selection. All assemblies were
checked by remapping fastq reads to assembled genomes and by aligning to the respective reference
genomes. Of the total 246 genomes assessed, three (HPV42, HPV53, HPV56) were discarded from
further analysis due to chimeric artefacts.
HPV Detection
For HPV detection and genotyping, quality controlled and dehumanized fastq-files from (trimmed
and filtered against human genome as described above) were mapped with Bowtie2 to a reference set
of 318 HPV sequences downloaded from PaVE (https://pave.niaid.nih.gov/, accessed in November
2018) and one novel genotype detected in our laboratory. Accession numbers of reference genomes are
provided in Supplementary Table S1 [27].
Samples were considered positive if at least one concordantly mapping read pair was detected
covering a minimum of 150 bp of the reference genome. To avoid possible mapping artefacts reads
covering < 200 bp with the mutation rate > 0.03 (~4.5 variants on 150 bp read) were blasted against
NCBI-based database (built on July 2019) and manually/visually checked. Artefacts were removed if
the blast provided different results.
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2.4. Phylogenetic Analysis and Lineage Classification
Complete HPV genomes obtained in this study (n = 243) were assessed to investigate HPV variant
distribution in healthy women in Luxembourg. Complete genomes were linearized according to
the respective reference sequence available in PaVE (https://pave.niaid.nih.gov/) [27] and aligned
using MAFFT [41]. Each HPV isolate genome was classified into lineage or sublineage using the
p-distance method and phylogenetic analysis with respective reference [3,4,13]. For the phylogenetic
analysis the evolutionary history was inferred using RAxML method employing 1000 bootstrap
values [42]. P-distance calculation was done in MEGA7 [43]. For HPV genomes with well-established
lineages/sublineages we used the respective reference lineages and sublineages in PaVE and
Chen et al. [13], whereas for HPVs with no established lineages/sublineages all complete genomes
available in NCBI were downloaded for analysis (Supplementary Table S2). Phylogenetic trees
were visualized in iTOL5.3 and Dendroscope 3 [44,45]. Plots were constructed in R (scripts available
on request).
2.5. Statistical Analysis
Statistical analysis was performed using STATA 14 (College Station, TX, USA). We estimated HPV
genotyping concordance by the percentage agreement and Cohen’s kappa (k). Cohen’s kappa values
less than zero were classified as no agreement, 0.00–0.19 as poor, 0.20–0.39 as fair, 0.40–0.59 as moderate,
0.60–0.79 as good and 0.80–1.00 as excellent, as proposed in VALGENT [46,47]. Agreement, concordance
and discordance were assessed restricting analysis to 28 genotypes included in the Anyplex II HPV28
assay and 729/744 samples with results available by both methods. Fully concordant samples were
defined when all genotypes were detected by both Anyplex and NGS. Partially concordant samples
were defined if at least one genotypes was shared by the two methods and discordant samples were
defined as those where no genotypes were shared.
2.6. Data Access
Complete genomes generated during the study have been submitted to the European Nucleotide
Archive (ENA) repository and are available under accession numbers LR861810, LR861811, LR861836–
LR861981, LR861983, LR861984, LR861986, LR861987, LR861989, LR861990, LR861992–LR862007,
LR862010, LR862011, LR862014, LR862015, LR862017, LR862018, LR862020–LR862086 (Supplementary
Table S3). Sequence alignments are included in supplementary files. Accession numbers for genomes
downloaded from GenBank are provided in Supplementary Tables S1 and S2.
2.7. Ethical Approval
The study was approved by the Comité National d’Ethique de Recherche (CNER # 201501/02) and
authorized by the Commission Nationale pour la Protection des Données (CNPD 288/2016).
3. Results
3.1. NGS and Anyplex II HPV 28
Overall, HPV positivity was 366/729 (50.2%) by Anyplex and 332/729 (45.5%) by NGS.
From 28 genotypes covered by Anyplex, NGS detected 25 (all except HPV11, HPV26, HPV69)
plus 41 additional genotypes in 171 (23.5%) samples, of which 43/171 (25.1%) were negative by Anyplex.
Anyplex detected 146 genotypes in 97 samples negative by NGS. Overall, Anyplex detected 778 and
NGS detected 888 type-specific infections, corresponding to an average of 1.1 and 1.2 genotypes per
sample, respectively.
When considering only positive samples, the average number of genotypes detected per sample
was 2.1 for Anyplex and 2.7 for NGS. Multiple genotypes were detected in 200/366 (54.6%, range 0–7)
of the samples with Anyplex and 204/332 (61.4%, range 0–14) with NGS. Anyplex viral load was
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significantly associated with the count of reads mapping to HPV by NGS (p < 0.001) (Table 1). The top
three most-frequently detected hr genotypes by Anyplex were HPV51 (5.8%), HPV58 (5.7%) and
HPV68 (5.3%), while the top three genotypes by NGS were HPV51 (6.1%), HPV56 (4.3%) and HPV66
(3.7%) (Figure 1A). The most-frequently detected lr-HPV by both methods were HPV42 and HPV53
(Figure 1B). HPV67 (3.6%), HPV90 (3.0%), HPV62 (2.6%), HPV89 (2.5%) and HPV87 (2.3%) were the
most-frequently observed genotypes detected by NGS (not targeted by Anyplex) (Figure 1C).
Table 1. Proportion of genotypes detected by next generation sequencing (NGS) stratified by viral load
as determined by Anyplex II HPV28.
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General agreement for overall HPV positivity of 28 genotypes between the two methods was 
80.8% (kappa = 0.616) (good concordance). When restricting the analysis to medium and high viral 
load results (++/+++), agreement was higher (86.3%) with a kappa value of 0.712 (good concordance). 
Agreement for 14 hr HPV positivity was 84.8% with kappa value of 0.65 (good concordance). 
Similarly, when restricting analysis to medium and high viral load (++/+++) agreement for 14 hr-HPV 
was slightly higher (87.1%, kappa = 0.69) (good concordance) (Table 2). Type-specific agreement is 
reported in Supplementary Table S4. Among 398/729 (54.6%) HPV positive samples by either method, 
we observed 115/398 (28.9%) fully concordant samples down to genotype level, also considering 
infections with multiple genotypes. 
Table 2. Overall agreement for HPV detection between Anyplex II HPV28 and next-generation 
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Figure 1. (A,B) Frequency distribution of hu an papillomavirus (HPV) genotypes detected by
Anyplex II HPV28 and next-generation sequencing: (A) high-risk genotypes, (B) low-risk genotypes.
Grey bars indicate genotypes detected by both methods, orange bars indicate genotypes detected by
Anyplex II HPV28 only, and blue bars indicate genotypes detected by next-generation sequencing only.
(C) Frequency distribution of HPV genotypes detected by next-generation sequencing only.
General agreement for overall PV positivity of 28 genotypes between the two methods was
80.8% (kappa = 0.616) (good concordance). When restricting the analysis to medium and high viral
load results (++/+++), agreement was higher (86.3%) with a kappa value of 0.712 (good concordance).
Agreement for 14 hr HPV positivity was 84.8% with kappa value of 0.65 (good concordance). Similarly,
when restricting analysis to medium and high viral load (++/+++) agreement for 14 hr-HPV was slightly
higher (87.1%, kappa = 0.69) (good concordance) (Table 2). Type-specific agreement is reported in
Supplementary Table S4. Among 398/729 (54.6%) HPV positive samples by either method, we observed
115/398 (28.9%) fully concordant samples down to genotype level, also considering infections with
multiple genotypes.
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Table 2. Overall agreement for HPV detection between Anyplex II HPV28 and next-generation sequencing.
HPV Types 1 A+/NGS+ 2 A+/NGS− 3 A-/NGS+ 4 A-/NGS− 5 % Agreement Kappa (se)
Interp-
Retation 6




(++/+++) 8 236 46 54 393 86.3
0.712
(0.037) G




(++/+++) 10 167 52 42 468 87.1
0.689
(0.037) G
A, Anyplex; NGS, next generation sequencing; se, standard error. 1 Number of reads per sample restricted to
28 genotypes detectable by Anyplex. 2 A+/NGS+, positive with both methods. 3 A+/NGS-, Anyplex positive
and NGS negative. 4 A-/NGS+, Anyplex negative and NGS positive. 5 A-/NGS-, negative with both methods.
6 Interpretation of the kappa values: P, poor; F, fair; M, moderate; G, good; E, excellent [47]. 7 Analysis restricted
to 28 HPV types detectable by Anyplex. 8 Analysis restricted to 28 HPV types detectable by Anyplex, Anyplex
positivity is restricted to medium or high viral load (++/+++). 9 Analysis is restricted to 14 high-risk HPV
(HPV16,18,31,33,35,39,45,51,52,56,58,59, 66 and 68) [5]. 10 Analysis is restricted to 14 high-risk HPV, Anyplex
positivity is restricted to viral load medium or high (++/+++).
3.2. HPV Variant Distribution and Lineage Classification
We obtained 232 complete alpha HPV and 11 gamma HPV genomes from 153 samples (Figure 2)
spanning 40 different HPV types. The most-frequently obtained complete genomes were HPV51
(9.1%), HPV42 (8.6%), HPV53 (8.6%) and HPV59 (7.4%) (Tables 3 and 4 and Supplementary Table S3).
Phylogenetic trees were created for each isolate and topologies were evaluated to classify our genomes
to the existing or novel lineages/sublineages as described before [4]. Reference HPV genomes were
considered as the prototype sequence, which were always assigned as lineage A or sublineage A1
(Supplementary Table S2).
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Of a total 243 complete genomes, 49 (13 hr and 36 lr-HPV) were classified as belonging to 17 novel
lineages and 14 novel sublineages of 20 HPV types including 4 hr and 16 lr-HPV genotypes (Tables 3 and 4,
Figures 3 and 4 and Supplementary Figure S2). The remaining 194 complete genomes clustered with
46 existing lineages and 51 sublineages (Supplementary Figures S3 and S4).























α-9 HPV16 2 566 10 7906–7907 36 A1 -
α-9 HPV31 11 29 7 7878–7920 37 A1, B2, C2–C3 -
α-9 HPV33 2 29 5 7833–7911 36 A1–A2 -
α-9 HPV35 2 30 2 7879–7880 36 A1 -
α-7 HPV39 11 22 3 7817–7885 40 A1–A2 -
α-7 HPV45 3 23 5 7849–7866 39 A1, B2 C
α-5 HPV51 22 31 6 7811–7815 39 A1–A3, B1 -
α-9 HPV52 7 93 7 7933–7962 38 A1–A2, E
α-6 HPV56 12 13 3 7790–7866 37 A1–A2, B -
α-9 HPV58 8 149 8 7823–7825 37–38 A2, B1–B2 -
α-7 HPV59 18 14 4 7898–7913 38 A1, B1 B2
α-6 HPV66 15 16 3 7816–7824 38 A, B2 C
α-7 HPV68 5 31 10 7814–7835 39–40 A1–A2, B, F2 -
GC Content, guanine-cytosine content. 1 Total number of complete genomes available on NCBI/GenBank. 2 Number
of genomes downloaded from NCBI for the analysis. 3 Size of genomes sequenced in the study. For genotypes with
established lineages/sublineages in PaVE only reference variants were used. For genotypes with no established
lineages/sublineages in PaVE all complete genomes available in NCBI were used. See Supplementary Table S2 for
the list of downloaded genomes.























α-10 HPV6 4 214 4 8020–8032 40 B1, B3 –
α-6 HPV30 2 17 6 7843–7881 40 A2–A3 –
α-11 HPV34 4 17 5 7668–7788 37–38 A2, C2 D
α-8 HPV40 3 4 4 7905–7909 43 – A2–A4
α-1 HPV42 21 8 8 7901–7920 39 A1, A2 A3, B, C
α-8 HPV43 2 2 2 7986–8007 40 – B1–B2
α-10 HPV44 3 6 6 7822–7837 40–41 A, B –
α-6 HPV53 21 29 7 7859–7864 40 A, C, D1–D2 –
α-13 HPV54 6 12 5 7760–7776 41 A2 D
α-3 HPV61 1 12 4 7989 46 – A3
α-3 HPV62 3 4 4 8092–8092 45–46 A1 A2
α-9 HPV67 12 12 3 7806–7809 38 B1 B2
α-11 HPV73 7 16 3 7694–7716 36 A2, B C
α-7 HPV70 2 10 2 7905–7911 40 A –
α-10 HPV74 3 1 1 7893–7902 40–41 – B, C
α-5 HPV82 2 22 10 7868–7874 40 A3, B1 –
α-3 HPV84 2 1 1 7956–7974 46 – B1–B2
α-3 HPV87 4 4 4 7998–8001 45 A1 –
α-3 HPV89 1 4 4 8072 45 A2 –
α-14 HPV90 7 3 8016–8032 46 A1 A3, B
α-8 HPV91 4 1 1 7959–7959 40 – A2
γ-6 HPV101 2 1 1 7258–7259 43 – B, C
γ-6 HPV103 1 1 1 7263 41 – –
γ-6 HPV108 4 1 1 7158–7158 42 – B
γ-6 HPV214 1 1 1 7357 41 – –
γ-6 HPV226 2 1 1 7313–7315 42 B
γ-13 HPV213 1 - 7096 39 – –
GC Content, guanine-cytosine content. 1 Total number of complete genomes available on NCBI/GenBank. 2 Number
of genomes downloaded from NCBI for the analysis. 3 Size of genomes sequenced in the study. For genotypes with
established lineages/sublineages in PaVE only reference variants were used. For genotypes with no established
lineages/sublineages in PaVE all complete genomes available in NCBI were used. See Supplementary Table S2 for
the list of downloaded genomes.
Viruses 2020, 12, 1437 8 of 15
3.2.1. High-Risk HPV
In total, 118 complete hr-HPV genomes were assembled, spanning 24 existing lineages and 31
sublineages of 13 hr-HPV types (Supplementary Figure S3A–I). No complete genome of HPV18 could
be obtained. We characterized novel lineages of HPV45, HPV52, HPV66 and a novel sublineage of
HPV59 (Figure 3A–D). The novel lineage C of HPV45 differed by 0.93–1.35% and 1.38–1.39% from
lineages A and B, respectively. The difference between the novel lineage E of HPV52 and other lineages
ranged from 0.54% to 1.56%. Our analysis suggests that lineage B of HPV59 can be subdivided into
sublineages B1 and B2. The pairwise distance between sublineages B1 and B2 varied from 0.27% to
0.53%. The novel lineage C of HPV66 differed by 1.25–1.41% and 0.96–1.32% from lineages A and B,
respectively (Supplementary Table S5 and Figure 3A–D).
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3.2.2. Low-Risk HPV
In total, the 114 genomes obtained of 21 lr-HPV types clustered with 22 existing lineages and
20 sublineages (Supplementary Figure S4A–H). According to the pairwise distance an the phylogenetic
ana ysis, we identified 10 novel lineages (HPV34, HPV42, HPV43, HPV54, HPV73, HPV74, HPV84,
d HPV90) and 13 sublineag s (HPV40, 42, 3, 61, 62, 67, 8 , 90,
1 (Supplementary Figure S2A–M). The distance between new lineages with reference
variants varied betw en 0.86% and 5.12%, while distance between n w sublineages with the nearest
i t varied betwe n 0.3 % and 0.83% (Suppl mentary Table S5).
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3.2.3. Gamma HPV
We obtained 10 gamma-6 and one gamma-13 complete HPV genomes. In total, seven novel
variants were identified including lineages A, B, C of HPV101 and lineages A, B of HPV108 and HPV226
(Figure 4). The difference amongst HPV101 lineages varied from 1.30% to 2.51%. The distance between
A and B lineages was 1.59–1.68% for HPV108 and 1.07% for HPV226 (Supplementary Table S6). Variant
of HPV213 gamma-13 genotype differed by 0.77% from reference genome.
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4. Discussion
Our study showed a high diversity of human papillomavirus in women attending cervical cancer
screening. We characterized 243 complete HPV genomes of 40 different gen types and proposed the
classification of novel lineages/sublineages f r 4 hr-HPV and 16 lr-HPV genotypes. To the best of our
kn wledge, this is the first large scale study to present HPV diversity using unbiased NGS-RCA in
healthy young women and comparing the analytical performance of a PCR-based genotyping assay
with NGS-RCA.
Our findings suggest that the PCR-based the Anyplex assay is superior to the NGS in terms
of sensitivity since only 16% of genotypes with low viral load by the Anyplex were concordantly
identified by NGS. This is not surprising considering that Anyplex detection is based on type-specific
primers, whereas RCA is a random amplification of circular DNA. Nevertheless, NGS detected an
additional 110 genotypes compared to the Anyplex PCR. F rther, our study suggests that concordance
betwee the two methods increases with higher viral loads. In a recent clinical eval ation of the
Anyplex assay, the detection of cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) was
associ ted wit medium and hig viral loads of the 14 high-risk types only, but not with l w viral
loads or low-risk genotypes [48]. In our study, only 3.5% participants were diagnosed with abnormal
cytology, while we recovered 40% of complete genomes fr m these samples (Suppl mentary Table S7).
As such, it would be important to validate the NGS appr ach in a clinical context using established
protocol such as VALGENT [46].
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In total, we detected 66 different HPV genotypes including 90 lineages/sublineages, of which 27
were novel and not previously described. Although, the diversity of hr-HPV genotypes has been well
studied [4,13], we were able to identify novel variants of HPV45, HPV52, HPV59 and HPV66. Further,
we proposed the classification of 10 novel lineages and 13 sublineages of lr-HPV which has been less
studied. We were not able to obtain any complete HPV18 genomes (only five positive samples by both
methods) as ~50% of the study population received HPV vaccine [20,49].
Several NGS-based approaches have been trialed, including RNA-baits, PCR-based and untargeted
metagenomics [14,22,26,32,50–52]. Due to the high variability of HPV genomes across genera, species
and even genotypes, designing primers or baits with acceptable sensitivity in a cost-effective manner is
a major challenge. In our study, we found the untargeted rolling-circle amplification approach, initially
implemented for HPV sequencing by Meiring [53], to be a very useful tool for characterizing HPV
variants and detection. Identification of new variants could be important for adopting PCR-based
assays, as we observed substantial discordance in HPV type-specific genotyping of some hr and
lr HPVs.
Previous studies applied an RCA-based approach in immune-suppressed individuals, where high
viral load would facilitate HPV detection and complete genome recovery. Pastrana et al. reported
the discovery of 83 novel HPV types using RCA-NGS with the prior physical enrichment of viral
DNA from immunodeficient patients [32]. This method was successfully used for HPV detection and
characterization by researchers in South Africa and Brazil in HIV positive populations [14,53]. Results
of the study by Wang et al. suggest that RCA-based sequencing is more accurate than the long-PCR
template cloning and deep sequencing of HPV58 [54].
In our study, we obtained 243 HPV complete genomes, which increases the number of publicly
available complete HPV genomes on GenBank (~2283 complete genomes on April 2020) by approximately
10%. Our dataset provides important genomic insights on HPV variants where currently only a few
complete genomes were available, such as HPV42, HPV59, HPV66, HPV67, HPV90, and HPV91.
Interestingly, we also obtained 11 complete HPV genomes of gamma species, with a population
prevalence of 3.7% in our population. Our findings are in line with the previous research which found
gamma-6 species in cervical samples confirming their mucosal tropism [26,55–58]. Although gamma-6
pathogenicity is not well described, HPV108 could induce dysplasia in organotypic keratinocytes [57].
In our study, gamma-6 genotypes were present independently only in four samples, whereas other
23 samples were co-infected with other alpha HPVs. As gamma-6 HPV genotypes lack the E6 oncogene,
they may have a lower oncogenic potential [56].
One of the limitations of our study was the absence of negative and positive control during the
sequencing, in order to account for the cross contamination and index hopping. Therefore, our detection
criteria might produce some false positive results. Nevertheless, only 3% of the samples were defined
as HPV positive by NGS with at least one concordantly mapping read pair to the reference genome.
Moreover, when considering more stringent detection criteria for HPV positivity by NGS (mapping
coverage of 1000 bp), the agreement between methods did not change significantly (Supplementary
Table S8). The NGS detection threshold of concordant read pairs might have a higher impact on
genotyping results, rather than HPV positivity. We accounted for potential PCR or sequencing errors
during the assembly process by stringent quality controls and we excluded three genomes from the
analysis due to the presence of chimeric contigs.
The major advantage of the NGS method is that it requires no prior knowledge of which HPV
genotypes are present in the samples. Overall, we were able to detect 51 different HPV genotypes
including 26, which are not detectable by the Anyplex assay. As the majority of these HPV types belong
to IARC Group 3 (not classifiable as to its carcinogenicity to humans) [5], our findings currently do not
have direct clinical implications in the context of cervical cancer screening. Nevertheless, this approach
is certainly useful from a population and evolutionary biology perspective and may have potential to
address new disease etiology in the future.
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Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/12/1437/s1,
Figure S1A. Flow chart illustrating generation of blind assembly input data. Bar chart illustrating the generation
of the blind assembly input data. The bar labels show the average single read count over 744 samples. For HG
(Human Genome) we used genome version GRCh38. The average input size per sample for a blind genome
assembly is 93,675 reads, which corresponds on average to ~14% of the raw sample size. Figure S1B. Flow chart
illustrating generation of bowtie assembly input data. Bar chart illustrating the generation of the bowtie assembly
input data. The lower graph shows the generation of the genome assembly input data only considering HPV positive
samples. Figure S2A–M. Phylogenetic trees and pairwise distance comparisons for novel lineages/sublineages of
low-risk HPV complete genome variants. Phylogenetic trees were inferred from a global alignment of the complete
genome nucleotide sequences of the variants from following low risk HPV genotypes using RAxML: (A) HPV34,
(B) HPV40, (C) HPV42, (D) HPV43, (E) HPV54, (F) HPV61, (G) HPV62, (H) HPV67, (I) HPV73, (J) HPV74,
(K) HPV84, (L) HPV90, (M) HPV91. A star (
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lines of different colors to distinguish each lineage and sublineage. Genomes from our collection are indicated
with LNS identification number.
Author Contributions: A.L. and J.M. designed and conducted the study. A.L., A.W.-B. and J.M. designed
NGS pipelines. A.W.-B. implemented the NGS pipelines and contributed to methods part of the manuscript.
A.L. analyzed sequence data, performed the statistical analysis, interpreted findings and drafted the manuscript.
I.K. and Z.C. contributed to generating figures. J.T. performed HPV genotyping and next generation sequencing.
M.F.’s lab performed cytological testing. P.P. led recruitment at the Planning Familial. M.A., F.M., and S.W.,
advised and critically reviewed the manuscript. All authors have read and agreed to the published version of
the manuscript.
Funding: This work was supported by Fonds National de la Recherche Luxembourg [FNR grant no 14/BM/7932582
and PRIDE17/11823097]. M.A. was supported by the RISCC Network [grant no. 8478459], funded by the Horizon
2020 Programme for Research and Innovation of the European Commission (Brussels, Belgium).
Acknowledgments: We thank doctors at the Planning Familial (Sandrine Casarotto, Ulla Heckert-Hauck, Christine
Kalonji, Jacqueline Klein-Zimmermann, Brigitte Marchand, Anne-Laure Ricard-Michaux) as well the private
gynecologists (Annick Aerts, Jean-Marc Billion, Pascale George, Margareta Kirsch, Isabelle Meyer) for study
recruitment and sample collection. We thank Seegene for providing laboratory equipment for the duration of
the study.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Einstein, M.H.; Schiller, J.T.; Viscidi, R.P.; Strickler, H.D.; Coursaget, P.; Tan, T.; Halsey, N.; Jenkins, D.
Clinician’s guide to human papillomavirus immunology: Knowns and unknowns. Lancet Infect. Dis. 2009, 9,
347–356. [CrossRef]
2. de Villiers, E.M.; Fauquet, C.; Broker, T.R.; Bernard, H.U.; zur Hausen, H. Classification of papillomaviruses.
Virology 2004, 324, 17–27. [CrossRef]
3. Chan, P.K.; Zhang, C.; Park, J.S.; Smith-McCune, K.K.; Palefsky, J.M.; Giovannelli, L.; Coutlee, F.; Hibbitts, S.;
Konno, R.; Settheetham-Ishida, W.; et al. Geographical distribution and oncogenic risk association of human
papillomavirus type 58 E6 and E7 sequence variations. Int. J. Cancer 2013, 132, 2528–2536. [CrossRef]
4. Chen, Z.; Schiffman, M.; Herrero, R.; Desalle, R.; Anastos, K.; Segondy, M.; Sahasrabuddhe, V.V.; Gravitt, P.E.;
Hsing, A.W.; Burk, R.D. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related
variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS ONE 2011, 6, e20183. [CrossRef]
5. Bouvard, V.; Baan, R.; Straif, K.; Grosse, Y.; Secretan, B.; Ghissassi, F.E.; Benbrahim-Tallaa, L.; Guha, N.;
Freeman, C.; Galichet, L.; et al. A review of human carcinogens—Part B: Biological agents. Lancet Oncol.
2009, 10, 321–322. [CrossRef]
Viruses 2020, 12, 1437 13 of 15
6. Arbyn, M.; Tommasino, M.; Depuydt, C.; Dillner, J. Are 20 human papillomavirus types causing cervical
cancer? J. Pathol. 2014, 234, 431–435. [CrossRef]
7. Xi, L.F.; Kiviat, N.B.; Hildesheim, A.; Galloway, D.A.; Wheeler, C.M.; Ho, J.; Koutsky, L.A.
Human papillomavirus type 16 and 18 variants: Race-related distribution and persistence. J. Natl. Cancer Inst.
2006, 98, 1045–1052. [CrossRef]
8. Xi, L.F.; Schiffman, M.; Koutsky, L.A.; Hulbert, A.; Lee, S.K.; Defilippis, V.; Shen, Z.; Kiviat, N.B. Association of
human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2–3. Int. J. Cancer
2012, 131, 2300–2307. [CrossRef]
9. Mirabello, L.; Yeager, M.; Cullen, M.; Boland, J.F.; Chen, Z.; Wentzensen, N.; Zhang, X.; Yu, K.; Yang, Q.;
Mitchell, J.; et al. HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-
Genome Sequences in 3200 Women. J. Natl. Cancer Inst. 2016, 108. [CrossRef]
10. Godínez, J.M.; Heideman, D.A.M.; Gheit, T.; Alemany, L.; Snijders, P.J.F.; Tommasino, M.; Meijer, C.J.L.M.;
de Sanjosé, S.; Bosch, F.X.; Bravo, I.G. Differential presence of Papillomavirus variants in cervical cancer:
An analysis for HPV33, HPV45 and HPV58. Infect. Genet. Evol. 2013, 13, 96–104. [CrossRef]
11. Nicolás-Párraga, S.; Gandini, C.; Pimenoff, V.N.; Alemany, L.; de Sanjosé, S.; Bosch, F.X.; Bravo, I.G.; The RIS
HPV TT and HPV VVAP study groups. HPV16 variants distribution in invasive cancers of the cervix,
vulva, vagina, penis, and anus. Cancer Med. 2016, 5, 2909–2919. [CrossRef] [PubMed]
12. Xi, L.F.; Schiffman, M.; Koutsky, L.A.; Hughes, J.P.; Winer, R.L.; Mao, C.; Hulbert, A.; Lee, S.K.; Shen, Z.;
Kiviat, N.B. Lineages of oncogenic human papillomavirus types other than type 16 and 18 and risk for
cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 2014, 106. [CrossRef] [PubMed]
13. Chen, Z.; Schiffman, M.; Herrero, R.; DeSalle, R.; Anastos, K.; Segondy, M.; Sahasrabuddhe, V.V.; Gravitt, P.E.;
Hsing, A.W.; Chan, P.K.S.; et al. Classification and evolution of human papillomavirus genome variants:
Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and
Alpha-3 (HPV61). Virology 2018, 516, 86–101. [CrossRef] [PubMed]
14. Siqueira, J.D.; Alves, B.M.; Prellwitz, I.M.; Furtado, C.; Meyrelles, A.R.; Machado, E.S.; Seuanez, H.N.;
Soares, M.A.; Soares, E.A. Identification of novel human papillomavirus lineages and sublineages in
HIV/HPV-coinfected pregnant women by next-generation sequencing. Virology 2016, 493, 202–208. [CrossRef]
15. Jelen, M.M.; Chen, Z.; Kocjan, B.J.; Hošnjak, L.; Burt, F.J.; Chan, P.K.S.; Chouhy, D.; Combrinck, C.E.;
Estrade, C.; Fiander, A.; et al. Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates
and 78 Complete Genome Sequences. J. Virol. 2016, 90, 5503–5513. [CrossRef]
16. Poljak, M.; Valenčak, A.O.; Domjanič, G.G.; Xu, L.; Arbyn, M. Commercially available molecular tests for
human papillomaviruses: A global overview. Clin. Microbiol. Infect. 2020. [CrossRef]
17. Ostrbenk, A.; Xu, L.; Arbyn, M.; Poljak, M. Clinical and Analytical Evaluation of the Anyplex II HPV HR
Detection Assay within the VALGENT-3 Framework. J. Clin. Microbiol. 2018, 56. [CrossRef]
18. Hesselink, A.T.; Sahli, R.; Berkhof, J.; Snijders, P.J.; van der Salm, M.L.; Agard, D.; Bleeker, M.C.;
Heideman, D.A. Clinical validation of Anyplex II HPV HR Detection according to the guidelines for
HPV test requirements for cervical cancer screening. J. Clin. Virol. 2016, 76, 36–39. [CrossRef]
19. Latsuzbaia, A.; Tapp, J.; Nguyen, T.; Fischer, M.; Arbyn, M.; Weyers, S.; Mossong, J. Analytical performance
evaluation of Anyplex II HPV28 and Euroarray HPV for genotyping of cervical samples. Diagn. Microbiol.
Infect. Dis. 2016, 85, 318–322. [CrossRef]
20. Latsuzbaia, A.; Arbyn, M.; Tapp, J.; Fischer, M.; Weyers, S.; Pesch, P.; Mossong, J. Effectiveness of bivalent
and quadrivalent human papillomavirus vaccination in Luxembourg. Cancer Epidemiol. 2019, 63, 101593.
[CrossRef]
21. Arroyo, L.S.; Smelov, V.; Bzhalava, D.; Eklund, C.; Hultin, E.; Dillner, J. Next generation sequencing for
human papillomavirus genotyping. J. Clin. Virol. 2013, 58, 437–442. [CrossRef] [PubMed]
22. Muhr, L.S.A.; Bzhalava, D.; Lagheden, C.; Eklund, C.; Johansson, H.; Forslund, O.; Dillner, J.; Hultin, E.
Does human papillomavirus-negative condylomata exist? Virology 2015, 485, 283–288. [CrossRef] [PubMed]
23. Galati, L.; Brancaccio, R.N.; Robitaille, A.; Cuenin, C.; Luzi, F.; Fiorucci, G.; Chiantore, M.V.; Marascio, N.;
Matera, G.; Liberto, M.C.; et al. Detection of human papillomaviruses in paired healthy skin and actinic
keratosis by next generation sequencing. Papillomavirus Res. 2020, 9, 100196. [CrossRef] [PubMed]
24. Murahwa, A.T.; Meiring, T.L.; Mbulawa, Z.Z.A.; Williamson, A.-L. Complete Genome Sequences of Four
Novel Human Gammapapillomavirus Types, HPV-219, HPV-220, HPV-221, and HPV-222, Isolated from
Penile Skin Swabs from South African Men. Genome Announc. 2018, 6, e00584-18. [CrossRef] [PubMed]
Viruses 2020, 12, 1437 14 of 15
25. Kocjan, B.J.; Steyer, A.; Sagadin, M.; Hosnjak, L.; Poljak, M. Novel human papillomavirus type 174 from a
cutaneous squamous cell carcinoma. Genome Announc. 2013, 1, e00445-13. [CrossRef]
26. Latsuzbaia, A.; Arbyn, M.; Dutta, S.; Fischer, M.; Gheit, T.; Tapp, J.; Tommasino, M.; Weyers, S.; Mossong, J.
Complete Genome Sequence of a Novel Human Gammapapillomavirus Isolated from a Cervical Swab in
Luxembourg. Genome Announc. 2018, 6. [CrossRef]
27. Van Doorslaer, K.; Li, Z.; Xirasagar, S.; Maes, P.; Kaminsky, D.; Liou, D.; Sun, Q.; Kaur, R.; Huyen, Y.;
McBride, A.A. The Papillomavirus Episteme: A major update to the papillomavirus sequence database.
Nucleic Acids Res. 2017, 45, D499–D506. [CrossRef]
28. Mühr, L.S.A.; Eklund, C.; Dillner, J. Towards quality and order in human papillomavirus research. Virology
2018, 519, 74–76. [CrossRef] [PubMed]
29. Nelson, J.R.; Cai, Y.C.; Giesler, T.L.; Farchaus, J.W.; Sundaram, S.T.; Ortiz-Rivera, M.; Hosta, L.P.; Hewitt, P.L.;
Mamone, J.A.; Palaniappan, C.; et al. TempliPhi, phi29 DNA polymerase based rolling circle amplification of
templates for DNA sequencing. Biotechniques 2002, 32, 44–47. [CrossRef]
30. Rector, A.; Tachezy, R.; Van Ranst, M. A sequence-independent strategy for detection and cloning of circular
DNA virus genomes by using multiply primed rolling-circle amplification. J. Virol. 2004, 78, 4993–4998.
[CrossRef] [PubMed]
31. Murahwa, A.T.; Meiring, T.L.; Mbulawa, Z.Z.A.; Williamson, A.L. Discovery, characterisation and genomic
variation of six novel Gammapapillomavirus types from penile swabs in South Africa. Papillomavirus Res.
2019, 7, 102–111. [CrossRef]
32. Pastrana, D.V.; Peretti, A.; Welch, N.L.; Borgogna, C.; Olivero, C.; Badolato, R.; Notarangelo, L.D.; Gariglio, M.;
FitzGerald, P.C.; McIntosh, C.E.; et al. Metagenomic Discovery of 83 New Human Papillomavirus Types in
Patients with Immunodeficiency. mSphere 2018, 3. [CrossRef] [PubMed]
33. Brancaccio, R.N.; Robitaille, A.; Dutta, S.; Rollison, D.E.; Fischer, N.; Grundhoff, A.; Tommasino, M.; Gheit, T.
Complete Genome Sequence of a Novel Human Gammapapillomavirus Isolated from Skin. Genome Announc.
2017, 5, e00833-17. [CrossRef] [PubMed]
34. Latsuzbaia, A.; Hebette, G.; Fischer, M.; Arbyn, M.; Weyers, S.; Vielh, P.; Schmitt, F.; Mossong, J. Introduction
of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Diagn. Cytopathol. 2017, 45, 384–390. [CrossRef] [PubMed]
35. Brestovac, B.; Wong, M.E.; Costantino, P.S.; Groth, D. A rapid DNA extraction method suitable for human
papillomavirus detection. J. Med. Virol. 2014, 86, 653–657. [CrossRef]
36. Jung, S.; Lee, B.; Lee, K.N.; Kim, Y.; Oh, E.J. Clinical Validation of Anyplex II HPV HR Detection Test for
Cervical Cancer Screening in Korea. Arch. Pathol. Lab. Med. 2016, 140, 276–280. [CrossRef]
37. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. 2010. Available online:
http://www.bioinformatics.babraham.ac.uk/projects/fastqc (accessed on 15 November 2018).
38. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 2012, 9, 357–359.
[CrossRef]
39. Bankevich, A.; Nurk, S.; Antipov, D.; Gurevich, A.A.; Dvorkin, M.; Kulikov, A.S.; Lesin, V.M.; Nikolenko, S.I.;
Pham, S.; Prjibelski, A.D.; et al. SPAdes: A new genome assembly algorithm and its applications to single-cell
sequencing. J. Comput. Biol. 2012, 19, 455–477. [CrossRef]
40. Shean, R.C.; Makhsous, N.; Stoddard, G.D.; Lin, M.J.; Greninger, A.L. VAPiD: A lightweight cross-platform
viral annotation pipeline and identification tool to facilitate virus genome submissions to NCBI GenBank.
BMC Bioinform. 2019, 20, 48. [CrossRef]
41. Katoh, K.; Standley, D.M. MAFFT multiple sequence alignment software version 7: Improvements in
performance and usability. Mol. Biol. Evol. 2013, 30, 772–780. [CrossRef]
42. Stamatakis, A. RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies.
Bioinformatics 2014, 30, 1312–1313. [CrossRef] [PubMed]
43. Kumar, S.; Stecher, G.; Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger
Datasets. Mol. Biol. Evol. 2016, 33, 1870–1874. [CrossRef] [PubMed]
44. Letunic, I.; Bork, P. Interactive Tree Of Life (iTOL) v4: Recent updates and new developments.
Nucleic Acids Res. 2019, 47, W256–W259. [CrossRef] [PubMed]
45. Huson, D.H.; Scornavacca, C. Dendroscope 3: An interactive tool for rooted phylogenetic trees and networks.
Syst. Biol. 2012, 61, 1061–1067. [CrossRef]
Viruses 2020, 12, 1437 15 of 15
46. Arbyn, M.; Depuydt, C.; Benoy, I.; Bogers, J.; Cuschieri, K.; Schmitt, M.; Pawlita, M.; Geraets, D.; Heard, I.;
Gheit, T.; et al. VALGENT: A protocol for clinical validation of human papillomavirus assays. J. Clin. Virol.
2016, 76, S14–S21. [CrossRef] [PubMed]
47. Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33,
159–174. [CrossRef]
48. Baasland, I.; Romundstad, P.R.; Eide, M.L.; Jonassen, C.M. Clinical performance of Anyplex II HPV28 by
human papillomavirus type and viral load in a referral population. PLoS ONE 2019, 14, e0210997. [CrossRef]
49. Latsuzbaia, A.; Arbyn, M.; Weyers, S.; Mossong, J. Human papillomavirus vaccination coverage in
Luxembourg—Implications of lowering and restricting target age groups. Vaccine 2018, 36, 2411–2416.
[CrossRef]
50. Park, Y.; Lee, E.; Choi, J.; Jeong, S.; Kim, H.S. Comparison of the Abbott RealTime High-Risk Human
Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping
of HPV DNA. J. Clin. Microbiol. 2012, 50, 2359–2365. [CrossRef]
51. Li, T.; Unger, E.R.; Batra, D.; Sheth, M.; Steinau, M.; Jasinski, J.; Jones, J.; Rajeevan, M.S. Universal Human
Papillomavirus Typing Assay: Whole-Genome Sequencing following Target Enrichment. J. Clin. Microbiol.
2017, 55, 811–823. [CrossRef]
52. Li, T.; Unger, E.R.; Rajeevan, M.S. Universal human papillomavirus typing by whole genome sequencing
following target enrichment: Evaluation of assay reproducibility and limit of detection. BMC Genom. 2019,
20, 231. [CrossRef]
53. Meiring, T.L.; Salimo, A.T.; Coetzee, B.; Maree, H.J.; Moodley, J.; Hitzeroth, I.I.; Freeborough, M.J.; Rybicki, E.P.;
Williamson, A.L. Next-generation sequencing of cervical DNA detects human papillomavirus types not
detected by commercial kits. Virol. J. 2012, 9, 164. [CrossRef]
54. Wang, X.; Li, Y.; Ni, T.; Xie, X.; Zhu, J.; Zheng, Z.-M. Genome sequencing accuracy by RCA-seq versus long
PCR template cloning and sequencing in identification of human papillomavirus type 58. Cell Biosci. 2014,
4, 5. [CrossRef] [PubMed]
55. Chen, Z.; Schiffman, M.; Herrero, R.; Desalle, R.; Burk, R.D. Human papillomavirus (HPV) types 101 and
103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-
papillomaviruses. Virology 2007, 360, 447–453. [CrossRef] [PubMed]
56. Van Doorslaer, K.; McBride, A.A. Molecular archeological evidence in support of the repeated loss of a
papillomavirus gene. Sci. Rep. 2016, 6, 33028. [CrossRef] [PubMed]
57. Nobre, R.J.; Herraez-Hernandez, E.; Fei, J.W.; Langbein, L.; Kaden, S.; Grone, H.J.; de Villiers, E.M.
E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic
keratinocyte cultures. J. Virol. 2009, 83, 2907–2916. [CrossRef]
58. Ameur, A.; Meiring, T.L.; Bunikis, I.; Haggqvist, S.; Lindau, C.; Lindberg, J.H.; Gustavsson, I.; Mbulawa, Z.Z.;
Williamson, A.L.; Gyllensten, U. Comprehensive profiling of the vaginal microbiome in HIV positive women
using massive parallel semiconductor sequencing. Sci. Rep. 2014, 4, 4398. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
